ProShare Advisors LLC Has $142.25 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Francis Steltz on May 20th, 2026

ProShare Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 36.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 184,286 shares of the biopharmaceutical company’s stock after acquiring an additional 49,132 shares during the period. ProShare Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $142,245,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after purchasing an additional 26,884 shares in the last quarter. Dodge & Cox increased its holdings in Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after purchasing an additional 724,562 shares in the last quarter. Franklin Resources Inc. increased its holdings in Regeneron Pharmaceuticals by 6.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after purchasing an additional 139,647 shares in the last quarter. Capital World Investors increased its holdings in Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after purchasing an additional 32,348 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after purchasing an additional 408,649 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.1%

NASDAQ REGN opened at $630.30 on Wednesday. The business’s 50-day moving average price is $739.39 and its two-hundred day moving average price is $745.76. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market capitalization of $66.64 billion, a PE ratio of 15.36, a price-to-earnings-growth ratio of 1.40 and a beta of 0.30. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the company posted $8.22 EPS. The business’s revenue was up 19.0% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel Antibody-Helicon Conjugates across multiple therapeutic areas, a deal that could be worth up to about $2.2 billion in milestone payments plus royalties and expands REGN’s pipeline into “undruggable” targets. Article: Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Positive Sentiment: Several analysts still maintained constructive views on REGN despite trimming price targets, including buy/overweight calls from firms such as Canaccord, JPMorgan, Piper Sandler, BMO, and Wells Fargo, suggesting Wall Street still sees meaningful upside from current levels.
Neutral Sentiment: Regeneron’s latest earnings backdrop remains solid, with Q1 revenue up 19% year over year and results that beat consensus estimates, helping offset some of the pressure from recent headlines.
Negative Sentiment: The main driver of the stock’s weakness was a late-stage melanoma trial failure: fianlimab plus cemiplimab did not meet its primary progression-free survival endpoint versus Merck’s Keytruda, raising questions about the company’s near-term oncology growth prospects. Article: Regeneron drops after skin cancer treatment misses late-stage trial goal
Negative Sentiment: The trial miss triggered multiple analyst price-target cuts and a wave of shareholder-investigation headlines, adding to sentiment pressure and keeping attention on execution risk in REGN’s pipeline.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on REGN shares. Canaccord Genuity Group lowered their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

View Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.